Scientific Validation and Clinical Application of Lung Cancer Organoids

Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of nor...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dahye Lee, Yoonjoo Kim, Chaeuk Chung
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	lung neoplasms organoids culture media coculture techniques clinical study Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/44fd42bd9d9d45f583b66114e684648b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:44fd42bd9d9d45f583b66114e684648b
record_format	dspace
spelling	oai:doaj.org-article:44fd42bd9d9d45f583b66114e684648b2021-11-25T17:10:24ZScientific Validation and Clinical Application of Lung Cancer Organoids10.3390/cells101130122073-4409https://doaj.org/article/44fd42bd9d9d45f583b66114e684648b2021-11-01T00:00:00Zhttps://www.mdpi.com/2073-4409/10/11/3012https://doaj.org/toc/2073-4409Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets.Dahye LeeYoonjoo KimChaeuk ChungMDPI AGarticlelung neoplasmsorganoidsculture mediacoculture techniquesclinical studyBiology (General)QH301-705.5ENCells, Vol 10, Iss 3012, p 3012 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	lung neoplasms organoids culture media coculture techniques clinical study Biology (General) QH301-705.5
spellingShingle	lung neoplasms organoids culture media coculture techniques clinical study Biology (General) QH301-705.5 Dahye Lee Yoonjoo Kim Chaeuk Chung Scientific Validation and Clinical Application of Lung Cancer Organoids
description	Lung cancer organoid (LCO) is a novel model of lung cancer that facilitates drug screening. However, the success rate of LCOs varies from 7% to 87%, and the culture medium compositions are markedly different. Airway organoid media can be used for LCO cultures, but this promotes the overgrowth of normal cell organoids especially in LCOs from intrapulmonary lesions. Several modified media are specifically utilized for promoting the cancer cell’s growth. For culturing high-purity LCOs, cancer cells from metastatic lesions and malignant effusions are used. Recently, single-cell RNA sequencing has identified previously unknown cell populations in the lungs and lung cancer. This sequencing technology can be used to validate whether the LCO recapitulates the heterogeneity and functional hierarchy of the primary tumor. Several groups have attempted to culture LCOs with mesenchymal cells and immune cells to recapitulate the tumor microenvironment. Disease modeling using LCO provides novel insight into the pathophysiology of lung cancer and enables high-throughput screening for drug discovery and prognosis prediction. An LCO model would help to identify new concepts as a basis for lung cancer targeting by discovering innovative therapeutic targets.
format	article
author	Dahye Lee Yoonjoo Kim Chaeuk Chung
author_facet	Dahye Lee Yoonjoo Kim Chaeuk Chung
author_sort	Dahye Lee
title	Scientific Validation and Clinical Application of Lung Cancer Organoids
title_short	Scientific Validation and Clinical Application of Lung Cancer Organoids
title_full	Scientific Validation and Clinical Application of Lung Cancer Organoids
title_fullStr	Scientific Validation and Clinical Application of Lung Cancer Organoids
title_full_unstemmed	Scientific Validation and Clinical Application of Lung Cancer Organoids
title_sort	scientific validation and clinical application of lung cancer organoids
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/44fd42bd9d9d45f583b66114e684648b
work_keys_str_mv	AT dahyelee scientificvalidationandclinicalapplicationoflungcancerorganoids AT yoonjookim scientificvalidationandclinicalapplicationoflungcancerorganoids AT chaeukchung scientificvalidationandclinicalapplicationoflungcancerorganoids
_version_	1718412644925308928

Scientific Validation and Clinical Application of Lung Cancer Organoids

Ejemplares similares